Renal and cardiac effects of DPP-4 inhibitors - from preclinical development to clinical research

Kidney and Blood Pressure Research

Volumn 36, Issue 1, 2012, Pages 65-84

  Hocher, Berthold ^a,b   Reichetzeder, Christoph ^a,b   Alter, Markus L ^a,b,c  

^a UNIVERSITY OF POTSDAM   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute renal failure; Cardiovascular effects; DDP 4 inhibition; Diabetes; Diabetic nephropathy; GLP 1; Kidney; Myocardial infarction

Indexed keywords

ALOGLIPTIN; CAPTOPRIL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; HYDRALAZINE; ISOLEUCINE THIAZOLIDIDE; LINAGLIPTIN; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL RESEARCH; CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK;

BIOMEDICAL RESEARCH; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HEART; HUMANS; KIDNEY;

EID: 84865576863     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000339028     Document Type: Review

References (112)

1. Anon.: CDC - 2005 National Diabetes Fact Sheet - Publications - Diabetes DDT
2. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431.
3. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13:S1-68.
4. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
5. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
7. Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:S789-830.
8. DeSouza C, Fonseca V: Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov 2009;8:361-367.
9. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
10. Kendall DM, Rubin CJ, Mohideen P, Ledeine J-M, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016-1023.
11. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE: (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-151.
12. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan C-C, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-2994.
13. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-688.
14. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619.
15. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA: Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-1864.
16. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S: Efficacy and tolerability of vildagliptin monotherapy in drugnaïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-138.
17. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-895.
18. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-428.
19. Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S: Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30:3017-3022.
20. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE: 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2- cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-2789.
21. Brandt I, Joossens J, Chen X, Maes M-B, Scharpé S, De Meester I, Lambeir A-M: Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2- carbonitrile). Biochem Pharmacol 2005;70:134-143.
22. He Y-L, Sabo R, Campestrini J, Wang Y, Ligueros-Saylan M, Lasseter KC, Dilzer SC, Howard D, Dole WP: The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007;63:677-686.
23. He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D: Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009;37:536-544.
24. He Y-L, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, Howard D: The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007;46:787-802.
25. GALVUS®: SUMMARY OF PRODUCT CHARACTERISTICS
26. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M: (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-182.
27. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA: Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009;25:1963-1972.
28. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-1178.
29. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA: Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009;11:786-794.
30. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K: The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-678.
31. Fuchs H, Tillement J-P, Urien S, Greischel A, Roth W: Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009;61:55-62.
32. Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H: Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)-investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 2009;30:422-436.
33. Fura A, Khanna A, Vyas V, Koplowitz B, Chang S-Y, Caporuscio C, Boulton DW, Christopher LJ, Chadwick KD, Hamann LG, Humphreys WG, Kirby M: Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009;37:1164-1171.
34. ONGLYZA®: SUMMARY OF PRODUCT CHARACTERISTICS
35. Patel CG, Kornhauser D, Vachharajani N, Komoroski B, Brenner E, Handschuh del Corral M, Li L, Boulton DW: Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes Metab 2011;13:604-614.
36. Boulton D, Geraldes M: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-Daily Oral Doses of Saxagliptin for 2 Weeks in Type 2 Diabetic and Healthy Subjects. in: 67th Annual Scientific Sessions of the American Diabetes Association. 2007.
37. Boulton DW, Li L, Frevert EU, Tang A, Castaneda L, Vachharajani NN, Kornhauser DM, Patel CG: Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-265.
38. Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ: Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 2008;589:306-314.
39. Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30:513-527.
40. Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30:499-512.
41. Karim A, Covington P, Christopher R, Davenport M, Fleck P, Li X, Wann E, Mekki Q: Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010;48:46-58.
42. Karim A, Fleck P, Hetman L: Single-Dose Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Subjects with Renal Impairment. in: 68th Annual Scientific Sessions of the American Diabetes Association. 2008.
43. Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q: Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009;49:1210-1219.
44. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R, Santos P, Velada I, Melo A, Nunes S, Teixeira F, Reis F: Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010;2010:592760.
45. Matsui T, Nishino Y, Takeuchi M, Yamagishi S: Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011;63:383-388.
46. Jost MM, Lamerz J, Tammen H, Menzel C, De Meester I, Lambeir A-M, Augustyns K, Scharpé S, Zucht HD, Rose H, Jürgens M, Schulz-Knappe P, Budde P: In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. Biochem Pharmacol 2009;77:228-237.
47. Dobrian AD, Ma Q, Lindsay JW, Leone KA, Ma K, Coben J, Galkina EV, Nadler JL: Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 2011;300:E410-E421.
48. Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharpé S, Kupiec-Weglinski JW: Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997;63:1495-1500.
49. Korom S, de Meester I, Belyaev A, Schmidbauer G, Schwemmle K: CD26/DPP IV in experimental and clinical organ transplantation. Adv Exp Med Biol 2003;524:133-143.
50. Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H, Runge F, Klein T, Hocher B: Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS ONE 2011;6: e27861.
51. Alter M, Ott I, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Klein T, Hocher B: DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res DOI: 10.1159/000341487.
52. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968-2978.
53. Wei Y, Mojsov S: Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996;157:355-357.
54. Huisamen B, Genade S, Lochner A: Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr 2008;19:77-83.
55. Huisamen B, Genis A, Marais E, Lochner A: Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011;25:13-20.
56. Gardiner SM, March JE, Kemp PA, Bennett T, Baker DJ: Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats. Br J Pharmacol 2010;161:92-102.
57. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP: Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699.
58. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen Y-T, Elahi D, Shannon RP: Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005;312:303-308.
59. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen Y, Shannon RP: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-961.
60. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965.
61. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-151.
62. Sauvé M, Ban K, Momen MA, Zhou Y-Q, Henkelman RM, Husain M, Drucker DJ: Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice. Diabetes 2010;59:1063-1073.
63. Ku H-C, Chen W-P, Su M-J: GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 2010;382:463-474.
64. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-2350.
65. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS: Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003;362:697-703.
66. Kollet O, Shivtiel S, Chen Y-Q, Suriawinata J, Thung SN, Dabeva MD, Kahn J, Spiegel A, Dar A, Samira S, Goichberg P, Kalinkovich A, Arenzana-Seisdedos F, Nagler A, Hardan I, Revel M, Shafritz DA, Lapidot T: HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest 2003;112:160-169.
67. Stokman G, Stroo I, Claessen N, Teske GJD, Florquin S, Leemans JC: SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrology Dialysis Transplantation 2010;25:3852-3859.
68. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T: The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol DOI: 10.1016/j.ijcard.2011.12.007.
69. Zaruba M-M, Theiss HD, Vallaster M, Mehl U, Brunner S, David R, Fischer R, Krieg L, Hirsch E, Huber B, Nathan P, Israel L, Imhof A, Herbach N, Assmann G, Wanke R, Mueller-Hoecker J, Steinbeck G, Franz W-M: Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009;4:313-323.
70. Zhang D, Huang W, Dai B, Zhao T, Ashraf A, Millard RW, Ashraf M, Wang Y: Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts. Am J Physiol Heart Circ Physiol 2010;299:H1339-1347.
71. Theiss HD, Brenner C, Engelmann MG, Zaruba M-M, Huber B, Henschel V, Mansmann U, Wintersperger B, Reiser M, Steinbeck G, Franz W-M: Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis. Int J Cardiol 2010;145:282-284.
72. Pacheco BP, Crajoinas RO, Couto GK, Davel APC, Lessa LM, Rossoni LV, Girardi AC: Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 2011;29:520-528.
73. Jackson EK, Dubinion JH, Mi Z: Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol 2008;35:29-34.
74. Mentlein R, Dahms P, Grandt D, Krüger R: Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993;49:133-144.
75. Berglund MM, Hipskind PA, Gehlert DR: Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 2003;228:217-244.
76. Dubinion JH, Mi Z, Zhu C, Gao L, Jackson EK: Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction. Hypertension 2006;47:545-551.
77. Marney A, Kunchakarra S, Byrne L, Brown NJ: Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010;56:728-733.
78. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS: Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340:248-255.
79. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H: Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-978.
80. Yang J, Campitelli J, Hu G, Lin Y, Luo J, Xue C: Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007;81:272-279.
81. Stefanovic V, Ardaillou N, Vlahovic P, Placier S, Ronco P, Ardaillou R: Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology 1993;80:465-470.
82. Vaghasiya J, Sheth N, Bhalodia Y, Manek R: Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul Pept 2011;166:48-54.
83. Girardi AC, Degray BC, Nagy T, Biemesderfer D, Aronson PS: Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 2001;276:46671-46677.
84. Schultheis PJ, Clarke LL, Meneton P, Miller ML, Soleimani M, Gawenis LR, Riddle TM, Duffy JJ, Doetschman T, Wang T, Giebisch G, Aronson PS, Lorenz JN, Shull GE: Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat Genet 1998;19:282-285.
85. Girardi ACC, Knauf F, Demuth H-U, Aronson PS: Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol, Cell Physiol 2004;287:C1238-1245.
86. Girardi ACC, Fukuda LE, Rossoni LV, Malnic G, Rebouças NA: Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 2008;294:F414-422.
87. Carraro-Lacroix LR, Malnic G, Girardi ACC: Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 2009;297:F1647-1655.
88. Tofovic DS, Bilan VP, Jackson EK: Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clin Exp Pharmacol Physiol 2010;37:689-691.
89. Jackson EK, Mi Z: Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 2008;51:1637-1642.
90. Jackson EK, Zhang M, Liu W, Mi Z: Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther 2007;323:431-437.
91. Kao DP, Kohrt HE, Kugler J: Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008;25:1229-1230.
92. Lestner JM, Baburaj R, Edwards CMB: Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity? Br J Hosp Med (Lond) 2011;72:412-413.
93. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346:1080-1084.
94. Forman JP, Brenner BM: "Hypertension" and " microalbuminuria": the bell tolls for thee. Kidney Int 2006;69:22-28.
95. Remuzzi G, Macia M, Ruggenenti P: Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006;17:S90-97.
96. Kalaitzidis R, Bakris G: Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich) 2009;11:636-643.
97. Alfie J, Aparicio LS, Waisman GD: Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. Rev Recent Clin Trials 2011;6:134-146.
98. Sharkovska Y, Alter M, Reichetzeder C, Tsuprykov O, Klein T, Hocher B: Linagliptin Offers a New Therapeutic Approach for ARB-Resistant Diabetic Nephropathy; in: 72nd Sci Sess of the American Diabetes Association (ADA), 2012, p 986-P.
99. Hattori S: Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011;58:69-73.
100. Groop P, Cooper M, Perkovic V, Emser A, von Eynatten M, Woerle H: Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment for Diabetic Nephropathy; in: 72nd Sci Sess of the American Diabetes Association (ADA), 2012, p 953-P.
101. Bethel M, Green J, Califf R, Holman R: Rationale and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes 2009;58:2152.
102. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W: Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-494.
103. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW: A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27.
104. Anon.: Clinical Trials.gov - The Vascular Effects of Vildagliptin in Insulin Resistant Individuals
105. Anon.: CAROLINA - Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
106. Anon.: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
107. Chaykovska L, Tsuprykov O, Hocher B: Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab 2011;57:455-467.
108. Hocher B, Ziebig R, Altermann C, Krause R, Asmus G, Richter C-M, Slowinski T, Sinha P, Neumayer H-H: Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol 2003;14:2329-2337.
109. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle H-J: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3.
110. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7.
111. White W, Gorelick P, Fleck P, Smith N, Wilson C, Pratley R: Cardiovascular Events in Patients Receiving Alogliptin: A Pooled Analysis of Randomized Clinical Trials; in: 70th Sci Sess of the American Diabetes Association (ADA), 2012, p 391-P.
112. Vickers SP, Cheetham SC, Birmingham GD, Rowley HL, Headland KR, Dickinson K, Grempler R, Hocher B, Mark M, Klein T: Effects of the DPP-4 Inhibitor, Linagliptin, in Diet-Induced Obese Rats: A Comparison in Naive and Exenatide-Treated Animals. Clin Lab 2012;58:787-799.